{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T05:24:37Z","timestamp":1786944277770,"version":"build-2736575974"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thyroid cancer research has shifted over the past three decades toward molecular classification, precision diagnostics and targeted therapy. However, the evolution of public research investment in this field has not been systematically characterized. This study analyzed National Cancer Institute (NCI)-administered thyroid cancer research funding from 1996 to 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a longitudinal portfolio analysis of NIH RePORTER records from fiscal years 1996\u20132025. NCI-administered projects with explicit thyroid cancer research relevance were identified through review of project titles, abstracts, public health relevance statements and project terms. The final analytic cohort comprised 753 project-award years (AYs). Rule-based dictionaries were used to annotate research stage, disease subtype, molecular target and therapeutic or diagnostic modality. Deduplicated project text was further analyzed using MedCPT biomedical embeddings and BERTopic to identify higher-order thematic domains.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort represented approximately USD 343.8 million in cumulative NCI funding in BRDPI-adjusted 2025 U.S. dollars. Annual research activity increased over time, peaking in 2015 with 53 active AYs and approximately USD 24.8 million in BRDPI-adjusted 2025 U.S. dollars. Translational or mixed clinical\u2013preclinical research accounted for the largest share of the portfolio (46.5%), and R01 awards were the dominant funding mechanism (48.5%). Papillary thyroid carcinoma was the most frequently annotated subtype, followed by anaplastic, differentiated, follicular, poorly differentiated and medullary thyroid cancers. BRAF, RET, MAPK\/MEK, PI3K\/AKT\/mTOR and RAS were the leading molecular targets. Topic modelling identified five higher-order thematic domains, suggesting a relative shift from broad thyroid cancer characterization toward diagnosis and risk stratification, molecular signaling, treatment-response biology and therapeutics for aggressive or advanced disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NCI-administered thyroid cancer research funding expanded between 1996 and 2025 and became increasingly translational, molecularly informed and clinically oriented. These findings provide an empirical map of public research investment in thyroid oncology and may help inform future funding priorities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1876183","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T04:34:46Z","timestamp":1786941286000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Thirty years of NCI thyroid cancer research investment (1996\u20132025): a longitudinal portfolio analysis of funding trends, molecular target emphasis and thematic evolution"],"prefix":"10.3389","volume":"16","author":[{"given":"Youfang","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Head and Neck Surgery, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Clinical Research Center for Cancer","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Clinical Research Center for Cancer","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrong","family":"Lai","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, Nanchang Medical College","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Le","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Clinical Research Center for Cancer","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(22)00035-3","article-title":"The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020","volume":"10","author":"Pizzato","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(24)00223-7","article-title":"Evolving epidemiological patterns of thyroid cancer and estimates of overdiagnosis in 2013\u201317 in 63 countries worldwide: a population-based study","volume":"12","author":"Li","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1644270","article-title":"Epidemiological study of thyroid cancer at global, regional, and national levels from 1990 to 2021: an analysis derived from the Global Burden of Disease Study 2021","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.26348","article-title":"Thyroid cancer: a review","volume":"331","author":"Boucai","year":"2024","journal-title":"Jama"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.2719","article-title":"Trends in thyroid cancer incidence and mortality in the United States, 1974-2013","volume":"317","author":"Lim","year":"2017","journal-title":"Jama"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.epi-21-1440","article-title":"Epidemiology of thyroid cancer","volume":"31","author":"Kitahara","year":"2022","journal-title":"Cancer Epidemiology Biomarkers Prev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41574-023-00920-6","article-title":"Genomic alterations in thyroid cancer: biological and clinical insights","volume":"20","author":"Landa","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188928","article-title":"Molecular basis and targeted therapy in thyroid cancer: progress and opportunities","volume":"1878","author":"Zhang","year":"2023","journal-title":"Biochim Biophys Acta (BBA)-Reviews Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17060939","article-title":"Prognostic significance of key molecular markers in thyroid cancer: a systematic literature review and meta-analysis","volume":"17","author":"Nguyen","year":"2025","journal-title":"Cancers"},{"key":"B10","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid\u00ae"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0115","article-title":"Dabrafenib versus dabrafenib+ trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial","volume":"32","author":"Busaidy","year":"2022","journal-title":"Thyroid"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02503","article-title":"Durability of response with selpercatinib in patients with RET-activated thyroid cancer: long-term safety and efficacy from LIBRETTO-001","volume":"42","author":"Wirth","year":"2024","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1201\/9781003515227-44","article-title":"Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0322","article-title":"Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma","volume":"31","author":"Dierks","year":"2021","journal-title":"Thyroid"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-0437","article-title":"Enhancing radioiodine incorporation into radioiodine-refractory thyroid cancer with MAPK inhibition (ERRITI): a single-center prospective two-arm study","volume":"28","author":"Weber","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1089\/thy.2023.0456","article-title":"Clinical outcomes of radioactive iodine redifferentiation therapy in previously iodine refractory differentiated thyroid cancers","volume":"34","author":"Toro-Tobon","year":"2024","journal-title":"Thyroid"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2025.101081","article-title":"Inequity of NIH cancer funding in the United States: an ecological study predicting funding based on disease burden from 2008 through 2023","volume":"45","author":"Berglas","year":"2025","journal-title":"Lancet Regional Health\u2013Americas"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2196\/60948","article-title":"Perceptions in 3.6 million web-based posts of online communities on the use of cancer immunotherapy: data mining using bertopic","volume":"27","author":"Wu","year":"2025","journal-title":"J Med Internet Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btad651","article-title":"Medcpt: contrastive pre-trained transformers with large-scale pubmed search logs for zero-shot biomedical information retrieval","volume":"39","author":"Jin","year":"2023","journal-title":"Bioinformatics"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2026.1773414","article-title":"Evolution of the NCI antibody-drug conjugate portfolio: from chemical engineering to clinical complexity","volume":"13","author":"Zhan","year":"2026","journal-title":"Front Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/ebm.2025.10389","article-title":"AI-powered topic modeling: comparing LDA and BERTopic in analyzing opioid-related cardiovascular risks in women","volume":"250","author":"Ma","year":"2025","journal-title":"Exp Biol Med (Maywood)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/jan.17041","article-title":"A retrospective study on the analysis of risk factors for bed fall events in hospitalised patients based on the BERTopic model","volume":"82","author":"Wang","year":"2026","journal-title":"J Adv Nurs"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.59852","article-title":"Overdiagnosis of papillary thyroid cancer","volume":"9","author":"Francis","year":"2026","journal-title":"JAMA Netw Open"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1346476","article-title":"Systemic treatments for radioiodine-refractory thyroid cancers","volume":"15","author":"Chen","year":"2024","journal-title":"Front Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03736-6","article-title":"SEOM-GETNE-TTCC clinical guideline thyroid cancer (2023)","volume":"26","author":"Alonso-Gordoa","year":"2024","journal-title":"Clin Transl Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07222-1","article-title":"Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition)","volume":"52","author":"Lin","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.epi-13-0242","article-title":"The clinical and economic burden of a sustained increase in thyroid cancer incidence","volume":"22","author":"Aschebrook-Kilfoy","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B30","doi-asserted-by":"publisher","first-page":"04090","DOI":"10.7189\/jogh.14.04090","article-title":"Assessing and projecting the global burden of thyroid cancer, 1990-2030: analysis of the Global Burden of Disease Study","volume":"14","author":"Zhao","year":"2024","journal-title":"J Glob Health"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.34890","article-title":"Allocation of National Institutes of Health funding by disease category in 2008 and 2019","volume":"4","author":"Ballreich","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00182-1","article-title":"Global funding for cancer research between 2016 and 2020: a content analysis of public and philanthropic investments","volume":"24","author":"McIntosh","year":"2023","journal-title":"Lancet Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2024.0084","article-title":"A scholarly dialog on recent trends in National Institutes of Health's funding for the thyroid field","volume":"34","author":"Hidalgo-\u00c1lvarez","year":"2024","journal-title":"Thyroid"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1172\/jci146925","article-title":"Changes in the National Cancer Institute\u2019s R01 workforce: growth, aging, retention, and policy implications","volume":"131","author":"Antman","year":"2021","journal-title":"J Clin Invest"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3362","article-title":"Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019","volume":"6","author":"Maniakas","year":"2020","journal-title":"JAMA Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.suc.2024.02.004","article-title":"The role of molecular markers in thyroid cancer diagnostics and treatment","volume":"104","author":"Sada","year":"2024","journal-title":"Surg Clinics North America"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1876183\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T04:34:52Z","timestamp":1786941292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1876183\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":36,"alternative-id":["10.3389\/fonc.2026.1876183"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1876183","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"article-number":"1876183"}}